A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

NCT02814097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Heart Failure

Interventions

DRUG: elamipretide
DRUG: Placebo

Sponsor

Stealth BioTherapeutics Inc.

Collaborators

[object Object]
[object Object]